Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARAMINE vs ANGIOTENSIN ll ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Treatment of hypotension due to certain acute medical conditions (e.g., spinal anesthesia, drug-induced hypotension),Off-label: adjunct in the management of septic shock
Treatment of hypotension in adults with septic or other distributive shock (FDA approved)
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Primarily hepatic via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
Primarily metabolized by aminopeptidases and other peptidases in plasma and tissues, with minimal hepatic involvement.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
Approximately 50-70% bound to albumin and alpha-1 acid glycoprotein.
Approximately 30% bound to plasma proteins, primarily albumin.
0.5-1.0 L/kg. Clinical meaning: Indicates extensive distribution into tissues, consistent with a polar catecholamine.
Approximately 0.3-0.5 L/kg; indicates distribution mainly in extracellular fluid.
Intramuscular: 100%; Subcutaneous: 100%; Oral: negligible (<5%) due to extensive first-pass metabolism.
Intravenous: 100%; subcutaneous/intramuscular: not well absorbed due to rapid local metabolism; oral: negligible (<1%) due to extensive first-pass metabolism.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to reduced clearance.
No specific dose adjustment required for renal impairment. Use caution in patients with renal artery stenosis.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to altered metabolism.
No specific dose adjustment required for hepatic impairment.
Intravenous infusion: 0.1-0.2 mg/kg/dose, titrate to effect; maximum 0.5 mg/kg/dose.
Intravenous infusion: 0.5-20 ng/kg/min titrated to effect. Safety and efficacy not established in neonates.
Use lower initial doses (e.g., 0.5-1 mg IV) and titrate slowly due to increased sensitivity and risk of hypertension.
Start at lower end of dosing range (1-5 ng/kg/min) due to potential for decreased renal function and increased sensitivity.
None
No boxed warnings.
Risk of extravasation leading to tissue necrosis,Use with caution in patients with hypertension, hyperthyroidism, or cardiovascular disease,May cause bradycardia reflexively,Monitor blood pressure closely during administration
Thrombotic and thromboembolic events: Increased risk of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, and myocardial infarction.,Ischemic events: May cause cardiac ischemia and reduce cardiac output; use with caution in patients with coronary artery disease.,Vascular thrombosis: High risk of vascular thrombosis in patients with a history of thrombosis or hypercoagulable states.,Use in hypovolemia: Correct hypovolemia before administration to avoid exacerbation of vasoconstriction.,Pregnancy: May cause fetal harm; avoid use in pregnant women unless potential benefit outweighs risk.
Hypersensitivity to metaraminol or any component,Use with MAO inhibitors (may cause severe hypertensive crisis),Use in patients with pheochromocytoma or severe hypertension
Hypersensitivity to angiotensin II acetate or any component of the formulation,No absolute contraindications listed by the manufacturer; however, use is avoided in patients with uncorrected hypovolemia and those with a history of thromboembolic events.
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs, but no specific dietary restrictions for metaraminol itself. Maintain adequate hydration as directed.
No food interactions specific to angiotensin II acetate. Maintain a balanced diet as tolerated. Avoid excessive salt intake unless directed otherwise, as it may counteract the medication's effect on blood pressure.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterine blood flow; may cause fetal bradycardia, hypoxia, or metabolic acidosis. Avoid in eclampsia.
First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, and death. Use contraindicated in pregnancy.
No human data. M/P ratio unknown. Excretion likely minimal due to high protein binding; exercise caution. Prefer alternative agents.
No data on M/P ratio. Likely excreted in breast milk. Avoid breastfeeding due to unknown risks to neonate.
Increased plasma volume may require higher initial doses. Titrate to effect; monitor for exaggerated pressor response. No fixed dose adjustment; individualize.
No dose adjustment recommended if used; however, if inadvertently exposed, discontinue drug. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may lower drug levels, but no established dose adjustment.
ARAMINE (metaraminol) is a potent vasopressor used primarily for acute hypotension. Monitor blood pressure frequently, ideally via intra-arterial line, as its duration of action is prolonged (up to 1 hour) and may cause rebound hypertension. Avoid extravasation; central line administration preferred. Tachyphylaxis can occur with prolonged use. It is contraindicated in patients with MAOI use within 14 days due to hypertensive crisis risk.
ANGIOTENSIN II ACETATE is a vasoconstrictor used for refractory hypotension in distributive shock. Administer via central line to avoid extravasation, which can cause severe tissue ischemia. Monitor blood pressure every 5 minutes during titration. Discontinue other vasopressors if possible to avoid additive arrhythmogenic effects. Use with caution in patients with coronary artery disease or previous myocardial infarction due to increased oxygen demand. Taper gradually to avoid rebound hypotension.
This medication is given intravenously to raise blood pressure during emergencies.,You will be closely monitored with frequent blood pressure checks and possible arterial line.,Report any chest pain, severe headache, or blurred vision immediately.,Inform your healthcare provider of all medications you take, especially antidepressants.,Do not stop or change the dose without medical advice.
This medication is given intravenously in the hospital to raise very low blood pressure. You will be closely monitored during treatment.,Inform your healthcare provider immediately if you experience chest pain, difficulty breathing, or irregular heartbeat.,Avoid sudden position changes to prevent dizziness, as blood pressure may fluctuate.,Report any pain, swelling, or color changes at the injection site, which could indicate medication leakage.,You may need regular blood tests to monitor kidney function and electrolyte levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARAMINE vs ANGIOTENSIN ll ACETATE, answered by our medical review team.
ARAMINE is a Vasopressor that works by Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.. ANGIOTENSIN ll ACETATE is a Vasopressor that works by Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARAMINE and ANGIOTENSIN ll ACETATE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARAMINE is: Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.. The standard adult dose of ANGIOTENSIN ll ACETATE is: Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARAMINE and ANGIOTENSIN ll ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARAMINE is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterin. ANGIOTENSIN ll ACETATE is classified as Category C. First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, sku. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.